Categories Earnings, Health Care

Abiomed, Inc. (NASDAQ: ABMD): Q3 2020 Earnings Snapshot

— Medical device maker Abiomed, Inc. (NASDAQ: ABMD) reported net income of $69.2 million or $1.51 per share for the third quarter of 2020, vs. $1.09 per share expected.

Abiomed, Inc. (NASDAQ: ABMD): Q3 2020 Earnings Snapshot

— Revenue increased 10% annually to $221.6 million during the three-month period, vs. $226.99 million expected

— US revenue rose 8% to $185.6 million, while overseas revenue moved up 29% to $36 million

— Third-quarter gross margin was 82%, down from 83% reported a year earlier

— Announced initiation of the ST-Elevation Myocardial Infarction Door-to-Unloading Pivotal Randomized Controlled Trial during the quarter

— Expects full-year 2020 revenue to be in the range of $846 million to $877 million, up 10% to 14% respectively

— Confirms full-year 2020 unadjusted operating margin guidance in the range of 28% to 30%

Listen to publicly listed companies’ earnings conference calls along with the edited closed caption text

Also Read:  FedEx (FDX) beats Q1 FY21 targets; stock rises

Most Popular

Major earnings conferences to watch this week

After registering a slow recovery in the first half of the week, the markets pared these gains on Thursday and Friday. The weakness witnessed in the latter half of the

Illumina (ILMN) is uniquely placed to offer long-term returns. Here’s why

Illumina, Inc. (NASDAQ: ILMN), a pioneer in genome sequencing technology, has strived to strengthen its unique position in the healthcare sector through strategic partnerships and technological innovation. Its performance so

The COVID-19 pandemic gave these companies an unexpected opportunity

The COVID-19 pandemic raged through the first half of this year and continues to impact the world without signs of abating. Amid this health crisis, several companies reported strong results

One thought on “Abiomed, Inc. (NASDAQ: ABMD): Q3 2020 Earnings Snapshot

Comments are closed.

Top